Clove & Clove Oil for Anti-Inflammatory

Research suggests that clove and clove oil, particularly through their primary active compound eugenol, demonstrate meaningful anti-inflammatory activity across a range of preclinical study designs, including animal models of carrageenan-induced swelling, topical emulsion and nanoemulsion formulations, and wound-healing experiments, with several studies reporting reductions in inflammatory markers and tissue responses comparable to standard reference drugs like diclofenac and indomethacin. Studies indicate that multiple bioactive constituents in clove, including eugenol, eugenyl acetate, and beta-caryophyllene, likely contribute to these effects through antioxidant and other biochemical pathways, and review articles broadly corroborate these findings by cataloguing eugenol's documented anti-inflammatory and analgesic properties across the published literature. The available evidence is drawn almost entirely from in vitro studies, animal experiments, and narrative reviews rather than human clinical trials, which represents a substantial limitation in drawing conclusions about effectiveness in people. Additionally, several reviews flag legitimate safety concerns, noting that eugenol can be toxic at higher concentrations, that existing research on its cytotoxicity and genotoxicity yields conflicting results, and that the therapeutic window observed in some animal studies was relatively narrow, meaning the overall picture, while promising, remains preliminary and warrants further well-controlled human research.